Holy Christ - I have been coming on less and since
Holy Christ - I have been coming on less and since Justafkas@le banned most everyone who didn’t bash this message board has become overwhelm with soft Bashers and Nadar haters. Not only are there more names posting negative crap but the frequency of the posts is like they have all day nothing better to do than question, bash, indeed doubt in anything positive and when they do they will “build up to break down” strategy of saying the drug is great but the CEO, or but the finances or but the trail, but the FDA. If your that unhappy with the CYDY stock sell. Ide be happy to buy more at these rock bottom cheap prices. I don’t want anyone to sell but its if it would shut up some of these complainersans make them disappear than See ya, don’t let the door hit you on the way out. I was wrong by neigh optimistic that EUA should have been granted already and that it was a lock but that doesn’t change my option that Leronlimab clearly showed plenty of benefit without risk and not 1 reason in the world it should not be EUA already other than big pharma heavy corrupt influence on FDA. If results were slightly better or had an even amount of 65+ Highest risk patients than FDA would not have a chair to sit at without giving approval, other countries would have been chomping at bit to buy whatever supply they could. I think as more health agencies have had almost a full week to digest and breakdown the results and the fact that 140 more people showing same outcome is not going to make results much better or much worse. They can get a 24% mortality reduction along with 6 less day stay in hospital and 166% better chance of walking out of hospital by day 28. Some countries don’t have all the SOC that leronlimab was compared against if we were in a trial against a sugar placebo nothing shot our numbers would all be pvalue met full approval and many countries have none of the SOC USA has and we still outperformed the best the US hospitals has to offer at every data point. I will be buying more every week until EUA. If it’s 1 week great, if it’s 3 months great I’ll have accumulated many more shares by then.
11
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...
Continue Reading
TORRAS Shines in Magnetic Stand Case Evaluation In the whirlwind of smartphone accessories, where the battle lines are drawn between protection and functionality, TORRAS has emerged victorious with its magnetic stand cases for the iPhone 18 Pro and its beefier brother, the iPhone 18 Pro Max. Expert Consumers—a trusted name in product evaluations—has given TORRAS the...
Continue Reading
A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...
Continue Reading
A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...
Continue Reading
Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...
Continue Reading
NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...
Continue Reading
Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...
Continue Reading
Massive Growth and Strategic Investment in DigitalXForce Now here’s a company that’s shaking things up—DigitalXForce. Right on the back of a staggering 514% growth, they’ve corralled a strategic investment from Arsenal Growth Equity. If you blink, you might miss just how fast they’re sprinting through the tech landscape. Institutional Support Backing the...
Continue Reading
Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Top 5 Most Recently Viewed Articles
N3on Partners with Iggy Azalea to Transform Online Gaming The partnership between N3on and Iggy Azalea marks an exciting evolution in the online gaming landscape, fusing pop culture with innovative technologies in the online casino space. This collaboration represents an incredible opportunity to reshape gaming entertainment by integrating a diverse array of experiences,...
Continue Reading
Quorum Information Technologies Reports Acquisition by Valsoft Quorum Information Technologies Inc. (TSX-V: QIS) has confirmed a definitive agreement for its acquisition by Valsoft Corporation, marking a strategic move for both companies. The all-cash transaction amounts to $0.80 for each outstanding common share of Quorum, a commendable offer that has been approved...
Continue Reading
Agreement Reached on Loan for Bay Area Transit Agencies In a significant development for the region, the Office of the Governor, the California Department of Finance, and the Metropolitan Transportation Commission (MTC) have announced a $590 million loan intended to support Bay Area transit agencies. This funding aims to prevent potential service cuts at critical transit...
Continue Reading
Uniti Group Inc. to Present at BofA Securities Conference Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) has recently announced an exciting opportunity for its leadership team to engage with investors during an upcoming financial conference. The company’s Senior Vice President, Chief Financial Officer, and Treasurer, Paul Bullington, along with Vice President of Investor...
Continue Reading
Fidelis Insurance Group's Upcoming Financial Results Announcement Fidelis Insurance Holdings Limited (NYSE:FIHL) is gearing up to share its financial performance for the fourth quarter that concluded in December 2024. This eagerly awaited release is scheduled for February 25, 2025, and will occur right after the financial markets conclude their daily functions. Investor...
Continue Reading
